$CVEO

Civeo Corporation (CVEO) sees 5.8% stake disclosed by American Century group

American Century entities and the Stowers Institute filed an SEC Schedule 13G for Civeo Corporation (CVEO). American Century Investment Management, American Century Companies, and Stowers each reported 640,269 shares, 5.8% of the class, with sole voting and dispositive power. American Century ETF Trust reported 615,126 shares, 5.6%.

Original reporting
Published Aug 14, 2026, 12:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2026, 1:08 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CVEO
Neutral
medium confidence
Mentioned
$CVEO
Relevance
5/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CVEONeutralLow
01

Why it matters

The disclosure establishes that these parties collectively hold about 5.8% (and the ETF trust 5.6%) of Civeo’s common stock with sole voting and dispositive power, but it does not describe activism or corporate actions.

02

Market read

This is a fresh ownership datapoint for CVEO, useful for monitoring shareholder concentration and potential future activism, but it is not a direct operational catalyst.

03

What to watch

Traders should check whether any other filings (e.g., Schedule 13D, additional amendments) follow, which would indicate a change from passive to active intent.

Relevance 5/10Novelty 5/10Timing: today’s read-through of a newly filed Schedule 13G ownership disclosure

Background

The article summarizes an SEC Schedule 13G amendment reporting beneficial ownership by American Century entities and the Stowers Institute for Medical Research.

Company-level read

Ticker impact

$CVEONeutralMedium confidence
Context

American Century entities disclosed passive beneficial ownership of 640,269 shares, or 5.8%, in Civeo common stock via SEC Schedule 13G.

Expected impact

Likely limited, with any move driven by sentiment around ownership concentration rather than fundamentals.

Evidence & confidence

The filing is a Schedule 13G beneficial ownership disclosure (passive, sole voting/dispositive power) and does not indicate an activist campaign, tender offer, or operational change.

Market effects

Minimal direct sector impact; this is company-specific ownership reporting rather than an industry catalyst.

None indicated.

None indicated.

Counterpoint

A 5.8% passive stake may be purely index or allocation-driven and may not change trading behavior meaningfully.

Key entities

  • Civeo Corporation

    Subject of the Schedule 13G beneficial ownership disclosure.

  • American Century Investment Management, Inc.

    Reported beneficial ownership of 640,269 shares (5.8%) with sole voting and dispositive power.

  • American Century Companies, Inc.

    Reported beneficial ownership of 640,269 shares (5.8%) as the parent controlling entity.

  • Stowers Institute for Medical Research

    Stated as controlling American Century Companies, Inc. per the filing.

  • American Century ETF Trust

    Reported beneficial ownership of 615,126 shares (5.6%) with sole voting and dispositive power.

Related articles

$CVEOMedAI 8/10

Civeo (CVEO) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 9:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Bradley Dodson Chief Financial Officer and Treasurer - Collin Gerry Vice President, Corporate Development - Regan Nielsen TAKEAWAYS Total Revenue -- $180 million, representing an 11% increase from $162.7 million in the prior year period. Net Loss -- $2.5 million, compared to a net loss of $3.3 million in the second quarter of 2025.

$CVEOMed

Civeo Corp (CVEO): Results of Operations and Financial Condition

Civeo Corp (CVEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cveo-06302026xrelease.htm EX-99.1 Document Civeo Reports Second Quarter 2026 Results Highlights: • Reported revenues of $180.0 million, net loss of $2.5 million and Adjusted EBITDA of $23.8 million; • Consolidated revenues increased 11%, driven by integrated services gr

$CVEOMedAI 8/10

Civeo Reports Second Quarter 2026 Results

Civeo (NYSE:CVEO) reported Q2 2026 revenues of $180.0M, net loss of $2.5M, and Adjusted EBITDA of $23.8M. Revenues rose 11% year over year, helped by integrated services and higher Canada occupancy. After quarter-end, it issued $115.0M 4.50% convertible notes due 2031 and repurchased 660,297 shares for about $22.3M.

$CVEOMedAI 8/10

Civeo Corporation Prices $100.0 Million Convertible Senior Notes Offering

Civeo (NYSE: CVEO) priced a $100.0 million offering of 4.50% convertible senior notes due 2031 in a Rule 144A private placement, settling July 7, 2026. Notes convert at 24.6840 shares per $1,000 (initial conversion price ~$40.51), ~20% above $33.76. Net proceeds ~$96.2 million; up to $110.8 million with option. Proceeds: $22.3 million to repurchase 660,297 shares and remainder to repay debt.

$CVEOMedAI 8/10

Civeo Awarded Six-Year Western Canada Contract Renewal

Civeo Corporation (NYSE: CVEO) said a Western Canada joint venture received a six-year contract renewal to provide workforce accommodations and hospitality services. The agreement runs through June 30, 2032, replacing arrangements due to expire in 2027, and covers services across Civeo’s Western Canada lodge network.